Canterbury DHB

Context

Microbial contamination of cellular therapy products

In the event of positive results, refer to the procedure 5017 Cellular Therapy Products with Positive Microbial Results.

Microbial contamination can occur at the collection, processing and storage steps of stem cell harvesting. Microbial contamination of PBSC varies between 1.6-4.5%. Most contamination is with coagulase-negative Staphylococci and no clinical sequelae are seen after infusion with prophylactic antimicrobial therapy. A death has been reported after re-infusion of Burkholderia cepacia and severe morbidity after MRSA. Institutional practice varies with regard to antibiotic prophylaxis. Not all true positives represent actual product contamination because cultures from parallel samples are frequently negative.

Management considerations of cellular therapy products with positive microbial cultures include:

About this Canterbury DHB document (112977):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

December 2016

Next Review:

December 2018

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 112977